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ABSTRACT 
Background. Antidepressant-induced liver injury is a major concern and a liver 
monitoring scheme has been recommended by the European Medicine Agency for agomelatine. 
Objective. To assess the liver safety and identify the characteristics of patients who 
developed a significant increase in transaminases whilst taking agomaatine. 
Method. A retrospective pooled analysis of changes in transaminase levels in 9,234 
patients treated with agomelatine (25mg or 50mg/day; n=7,605) or placebo (n=1,629) from 49 
phase II and III studies was undertaken. A significant increase in transaminase levels was 
defined as an increase to >3-fold the upper limit of normal (>3ULN). Final causality was 
determined in a case-by-case review by five academic experts.  
Results. Serum transaminase increased to >3ULN  in 1.3% and 2.5% of patients treated 
with 25mg and 50mg of agomelatine respectively, compared to 0.5% for placebo. The onset of 
increased transaminases occurred before 12 weeks in 64% of patients. The median time to 
recovery (to≤2ULN) was 14 days following treatment withdrawal. Liver function tests 
recovered in 36.1% patients despite continuation of agomelatine, suggesting the presence of a 
liver adaptive mechanism. No cases of acute liver failure or fatal outcome occurred. Patients 
with elevated transaminases at baseline, secondary to obesity/fatty liver disease, had an equally 
increased risk of developing further elevations of transaminases with agomelatine and placebo.  
Conclusion. Incidence of abnormal transaminases was low and dose-dependent. No 
specific population was identified regarding potential risk factors. Withdrawal of agomelatine 
led to rapid recovery, and some patients exhibited an adaptive phenomenon. Overall, in clinical 
trials, the liver profile of agomelatine seems safe when serum transaminases are monitored.  
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KEY POINTS 
- Incidence of agomelatine-induced transaminase increase is low and dose-dependent. 
- Withdrawal of agomelatine leads to rapid recovery. 
- Some patients exhibit an adaptative phenomenon. 
-  The liver profile of agomelatine seems safe when serum transaminases are monitored.  
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1. INTRODUCTION 
Agomelatine belongs to a new class of antidepressants. Agomelatine is a melatonergic 
agonist (MT1 and MT2 receptors) and serotonergic 2C (5-HT2C) antagonist. Binding studies 
indicate that agomelatine has no effect on monoamine uptake and no affinity for α- and β-
adrenergic, histaminergic, cholinergic, dopaminergic or benzodiazepine receptors [1, 2]. 
Agomelatine has no addictive properties and its abrupt cessation is not associated with any 
withdrawal symptoms [3]. 
Agomelatine was approved by the European Medicines Agency (EMA) in 2009 for 
treatment of major depressive episodes in adults [1]. The safety of agomelatine was assessed in 
a large number of phase II and phase III studies conducted by Servier and its US partner and 
included more than 14,000 patients. The most frequent adverse events include, by rank of 
frequency, headache, nausea, dizziness, somnolence, diarrhoea and dry mouth. 
Spontaneous reports of increase in liver transaminases have been reported in agomelatine-
treated patients. A liver monitoring scheme has been therefore recommended by the European 
Medicine Agency (EMA). Liver function tests should be performed before starting treatment 
and then after around 3 weeks, 6 weeks (end of acute phase), 12 and 24 weeks (end of 
maintenance phase), and thereafter when clinically indicated. When increasing the dosage, liver 
function tests should again be performed at the same frequency as when initiating treatment. 
Any patient who develops increased serum transaminases should have his/her liver function 
tests repeated within 48 hours. Agomelatine should be discontinued if the increase in 
transaminase exceeds 3 fold the upper limit of normal value (3ULN) [1]. 
Currently EMA and the MAH recommend that agomelatine is administered after careful 
consideration of benefit risk in patients with pre-existing liver diseases including fatty liver, 
obesity, diabetes, substantial alcohol intake or concomitant use of drugs with hepatotoxic 
potential. The scheme of liver monitoring and the data supporting the use of such criteria are 
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lacking. Of note, such data are also lacking for the other antidepressant. It is therefore difficult 
to draw conclusions about the prevalence, the severity the risk factors of antidepressant-induced 
liver injury. 
In this context of monitoring agomelatine-induced liver enzyme increase, we aimed to 
examine the incidence and characteristics of transaminase increase in patients treated with 
agomelatine who participated in phase II and III clinical trials. 
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2. METHODS 
2.1. Patients 
A retrospective pooled analysis of the hepatic safety of agomelatine was assessed in 
14,377 patients participating in all phase II and III trials conducted either by Servier or its US 
partner and completed by end 2013. The data come from 35 completed studies in major 
depressive disorders (N=12,307) and 14 completed studies for other indications (N= 2,070). 
Among 49 clinical studies, 28 are published [2, 4-30], 3 are submitted for publication, and the 
other were used for the European registration file. All studies were assessed by the EMA. All 
these studies included 7,605 patients treated with agomelatine (25-50mg) and 1,629 patients 
treated with placebo, and importantly this analysis only included patients in whom there was at 
least one post baseline value of transaminase. In the present analysis, in order to be able to 
extend our results to marketed doses of agomelatine, we focused our study to patients treated 
with 25 and 50 mg daily. We therefore excluded patients treated with other antidepressant, non-
marketed doses of agomelatine (1, 5, 10 and 100 mg) and patients for whom no information 
regarding transaminase levels under treatment was available (Figure 1). This left 9,234 patients 
treated with agomelatine or placebo for analysis. 
For the purpose of this analysis, an increase of transaminase was defined as significant 
when there was at least one value of ALT or AST>3ULN on treatment. The 3 fold ULN of 
transaminase is based on internationally recognised Guidance of DILI [31]. Of note, as 
transaminase dosage is highly variable among tests, we considered the upper limit of normal 
the value that was given by the laboratory for each test.  
 
2.2. Assessment of the causal relationship  
A Liver Safety Committee (LSC) which comprised five academic experts (4 hepatologists 
and 1 internist) was set up by Servier to monitor liver safety in agomelatine-treated patients. A 
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blinded case-by-case review was performed by the LSC. Experts were asked to classify all the 
cases to one of 4 classes of causality. These were 1) Probably related to the study treatment, 2) 
possibly related to the study treatment, 3) unlikely related to study treatment or 4) not related 
to study treatment (levels 1 to 4). 1) “Probably related” to the (study) treatment was used when 
the transaminase increase was clearly suggestive of a drug-related reaction in the absence of 
known confounding factors or in the presence of confounding factor(s) but less likely to have 
caused the event than the study drug; 2) “Possibly related” to the (study) treatment, as 
compatible with a drug-related reaction, in the absence of known confounding factors or in the 
presence of confounding factor(s) but not more likely than the study drug to have provoked the 
event; 3) “Unlikely related” to the (study) treatment, as compatible with a drug-related reaction, 
but with the presence of one or more confounding factors considered to be more likely than the 
study drug to have caused the increase in serum transaminase and/or an unusual pattern for a 
drug-induced reaction; 4) “Not related” to the (study) treatment, as clearly incompatible with a 
drug-related reaction and/or another cause (e.g acute hepatitis E) has been identified. In addition, 
a fifth causality category 5) Unknown: was used only for the first cases occurring before 2008 
in placebo-treated patients (N=7) and reviewed a posteriori in an unblinded condition. 
When there was no consensus of causality attributed to a patient, a consensus was 
achieved during a face to face meeting. Further, whenever an expert assigned causality as 
“probably related” the case was discussed face to face by all experts. In the few cases when 
consensus was not achieved, the highest level of causality was attributed. 
During the initial assessments, and once the drug administered was un-blinded, it became 
apparent that some patients developed an increase in transaminase which improved despite 
continuation of treatment. It therefore became evident that some patients exhibited what is now 
known as an adaptive phenomenon, enabling improvement or recovery despite continuation of 
treatment. 
Perlemuter G et al. Agomelatine and liver injury  9 
 
Hy’s law criteria were used to identify patient that could go on to develop acute liver 
failure: increase of ALT or AST higher than 3 ULN together with an increase of bilirubin higher 
than 2 ULN, in the absence of cholestasis and excluding those patients in whom an alternative 
cause was evident [31]. 
 
2.3. Statistical analyses 
Baseline descriptive statistics are provided for all patients: 7,605 treated with agomelatine 
25/50 mg/d and 1,629 placebo. Homogeneity of the distribution of the baseline characteristics 
are assessed using Student’s T-test for continuous variables and Pearson’s Chi-square test for 
categorical variables. 
Time to onset (i.e the number of days between first intake of agomelatine and the initial 
significant transaminase abnormality (>3ULN)), outcome and time to recovery were studied in 
patients assigned to being “probably or possibly related” only.  Recovery was defined as a return 
to normal values or values lower than those observed before the first intake of agomelatine, as 
being≤2ULN. Patients were considered as recovering when transaminase decreased to a 
level<3ULN. 
Unadjusted Cox proportional hazard models were used to estimate the effect of each 
potential risks factor, 95% CI and associated P-value in both the agomelatine and the placebo 
groups to confirm the identification of the potential risk factor. 
Treatment effect from unadjusted Cox proportional hazard models, 95% CI and associated 
P-value were provided by subgroup. P-value for interaction between treatment group and 
subgroup status was obtained by addition of interaction term of treatment and subgroup in the 
model. 
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3. RESULTS 
3.1 Patient’s characteristics 
Baseline characteristics of the 7,605 patients on agomelatine 25-50 mg/d and the 1,629 
patients on placebo are reported in Table 1. At inclusion, there was a higher number of patients 
with a BMI>30 kg/m² in the agomelatine group (22.56 %) than in the placebo group (19.52 %). 
However, the prevalence of high blood pressure, increase of AST, GGT and blood glucose was 
higher in the placebo group (Table 1). Of note, 7.76 % of patients in the agomelatine group and 
8.35 % in the placebo group had a baseline level of ALT higher than the upper limit of normal.  
 There were 139 patients with an increase of transaminase>3 ULN. Of these, 131 (1.7%) 
patients were taking agomelatine (25 or 50 mg/d) (Table 2), and 8 patients placebo (0.5%). Of 
the 131 patients with an increase of transaminase>3 ULN on agomelatine, 21 cases were 
assigned as probably related, 65 cases as possibly related, 32 cases as unlikely related and 13 
cases were considered unrelated to agomelatine (Figure 1). 
 
3.2. Incidence of increased transaminases > 3ULN  
The pooled incidence of increased serum transaminases to >3ULN in the 9,234 patients 
analysed was 1.3% and 2.5% in patients treated with 25 mg and 50 mg/d of agomelatine 
respectively (25 mg vs 50 mg/d, p<0.001), compared to 0.5% in placebo-treated patients 
(agomelatine 25 mg or 50 mg/d vs placebo, p<0.001).  
Twenty patients (0.3%) taking agomelatine exhibited a marked increase of 
transaminase>10 ULN (Table 2). Of these 20 patients, none had severe liver injury defined by 
the Hy’s law criteria. One patient had an increase of bilirubin level on agomelatine treatment at 
62 µmol/L. However, this case was classified as unlikely related to agomelatine due to the 
chronology of the event and a concomitant treatment with itraconazole. No cases of acute liver 
failure or fatal outcome were reported from the clinical trials.  
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3.3. Analysis of cases assigned as “possibly” or “probably related” 
When patients classified as “possibly or probably related” were analyzed, the observed 
frequency of increased transaminases was 0.8% and 1.7% with 25 mg and 50 mg/d of 
agomelatine, respectively, versus none on placebo (25-50 mg/d vs placebo p ≤ 0.001) (Table 
2). Of these patients, a daily dose of 50 mg agomelatine was associated with a higher proportion 
of patients with serum transaminase increase >10 ULN (0.3 %) compared to 25 mg/d (0.1%) 
(p=0.075) (Table 2). Overall, these data show a dose-relationship with a dose of 50 mg 
agomelatine/d being associated with a more frequent incidence of serum transaminases 
to>3ULN.   
We also assessed the time between the first intake of agomelatine and the first occurrence 
of transaminase increase>3ULN. The time to onset of increased serum transaminase > 3ULN 
occurred within the first 12 weeks of treatment in 64% of patients classified as “possibly or 
probably related to agomelatine” (Figure 2A). In 8.1% of patients classified as “possibly or 
probably”, the onset of transaminase increase occurred after 24 weeks of treatment.    
 
3.4. Outcome and liver adaptation 
All of the patients with an attributed possibly or probably agomelatine-induced 
transaminase increase for which a follow-up was available (96% of cases) recovered or were 
recovering. Three patients classified as “not recovered” had a limited follow up in time; in these 
patients, no significant change between maximum and last available transaminase value was 
notified. The median time to recovery was 14 days following treatment withdrawal. 
One striking observation was that many agomelatine-treated patients had an improvement 
or a normalization of transaminase level despite continuation of treatment. This phenomenon is 
called adpatation. Indeed, among the 86 patients in who the increase in serum transaminase>3 
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ULN  was attributed to being possibly or probably related to agomelatine, 31 (36.1%) cases 
demonstrated continued improvement or recovery despite continuation of agomelatine. 
Recovery of the transaminitis despite continuation of agomelatine was observed at both 25 mg/d 
(15 patients) and 50 mg/d (16 patients). The time between the first increase in serum 
transaminases and the first intake of agomelatine also occurred in the majority of patients with 
adaptation within the 12 first weeks of treatment (Figure 2B). The only difference found 
between patients with and without adaptation was a higher baseline level of GGT in patients 
without adaptation (Table 3). 
 
3.5. Risk factors for an increase in serum transaminases > 3ULN  
The EMA has recommended that patients with pre-existing fatty liver disease (non-
alcoholic fatty liver disease, NAFLD) are treated with agomelatine after careful consideration 
of benefit risk. In this context, we analysed factors that might be associated with significant 
increases in transaminase >3ULN. Sex and age were not associated with a risk of transaminase 
increase (Table 4). However, the presence of a baseline level for AST, ALT, GGT or 
triglyceride above the upper limit of normal, as well as metabolic syndrome mainly driven by 
obesity and elevated cholesterol was significantly associated with a higher risk to develop an 
increase of serum transaminase>3ULN in patients treated with agomelatine. In patients on 
placebo, a baseline level higher than the reference range for ALT and GGT was also associated 
with an increased risk of transaminase elevation>3ULN (Table 4). However, since the diagnosis 
of NAFLD relies on a fluctuation of transaminases between 1 to 3 ULN, the observation of an 
increase of transaminase in patients treated with agomelatine may be difficult to interpret. 
Therefore, to test whether NAFLD could be a risk factor of agomelatine-induced transaminase 
increase, we analysed whether an increased baseline of transaminase was associated with a 
higher risk of developing an elevation of transaminase higher than 3 ULN. Patients with an 
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increased baseline of transaminase were more at risk to developed a serum transaminase higher 
than 3ULN than patients with a normal baseline in both the placebo group (2.55% vs 0.27%), 
and the agomelatine group (3.41% vs 1.56%)  (Table 5). 
Patients with normal baseline transaminases had a higher risk of developing an increase 
of transaminase on agomelatine than on placebo (1.56% vs 0.27%; p<0.05) (Table 5). However, 
in patients with elevated baseline transaminase, the incidence of transaminase increase during 
treatment was not statistically different between agomelatine and placebo-treated patients 
(Table 4). These results suggest that the presence of a baseline elevation of transaminases, 
probably related to NAFLD, is not an additive risk of agomelatine-related transaminase increase. 
To distinguish between NAFLD and a more likely drug-induced liver injury in patients 
with a transaminase increase, we assumed that an increase of transaminases to >5 or 10ULN 
under treatment was more likely related to agomelatine rather than to the fluctuation of 
transaminases observed in NAFLD. We therefore compared the risk of transaminase increase>5 
and 10ULN between patients with normal or increased baseline level of transaminases (Table 
5). Again, there was no evident additive effect on the risk of ALT >5 or 10ULN under 
agomelatine treatment, in patients with an increased baseline level of ALT or AST (for 5 ULN: 
1.34 % vs 0.78%; for 10 ULN: 0.15% vs 0.27 %) (Table 5). 
Overall, these analyses suggest that a baseline elevation of transaminases, usually related 
to NAFLD, is not a risk for agomelatine-induced liver injury. 
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4. DISCUSSION  
This review of the cases of agomelatine induced hepatotoxicity as defined by a serum 
transaminase increase>3ULN in phase II and III clinical trials shows that incidence of 
transaminase increase was low and dose-dependent being 2.5% at a dose of 50 mg/day vs 1.3% 
at 25 mg/day. The majority of increases in serum transaminase occurred within the first 3 
months of treatment, and in particular between the forth and the twelfth weeks after the first 
intake of agomelatine.  
Antidepressant-induced liver injury remains a rare event  [33]. In a retrospective analysis 
of duloxetine safety in 23,983 subjects, an increase of ALT was observed in 13% of patients, 
12.7% of them (1.7% of total) having a value higher than 3ULN [34]. A study on venlafaxine 
safety that included 3000 patients showed an incidence of elevated transaminase levels (3ULN) 
of 0.4% [35]. Of note, in these studies, as well as the present analysis, the increase of 
transaminase was not necessarily related to the drug itself but may be due to many other causes 
including alcohol misuse, fatty liver disease, or viral hepatitis etc...  
We have tried to identify risk factors for transaminase increase in agomelatine-treated 
patients. Usually, female sex [36, 37] and older age [38] are considered as risk factors for DILI. 
We did not find such associations for agomelatine. We found that baseline serum transaminase 
greater than the upper limit of normal was associated with an increased risk of observing a 
serum transaminase>3ULN, in both agomelatine- and placebo-treated patients. These data were 
confounded by the fact that patients taking placebo were treated and monitored for 100 days 
with an average of 1.8 (± 0.9) tests per patient, whereas those taking agomelatine were treated 
for 160 days, with an average of 3.1 (± 3.5) tests/patient. Increased frequency of transaminases 
measurement is known to be associated with an increased incidence of transaminase elevation 
in placebo treated patients [32]. Non-alcoholic fatty liver disease (NAFLD) is the liver 
manifestation of the metabolic syndrome (REF PERLEMUTER). NAFLD is therefore 
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associated with overweight, insulin resistance, diabetes and dyslipidemia. NAFLD may 
progress from pure steatosis (fatty liver) to steatohepatitis, fibrosis and cirrhosis. Prevalence of 
NAFLD is high, about 23% of the general population, and increases to 74% among obese 
individuals [39]. Serum transaminase in patients with NAFLD can vary and be as high as 8-10 
ULN, but in most patients levels vary from to 1 to 4ULN. Our patients exhibited a relatively 
high prevalence of either being overweight (~31%) or obese (~22%) and ~9% had an elevated 
baseline serum transaminase, consistent with a high prevalence of NAFLD. Patients with 
NAFLD frequently exhibit marked variations in serum transaminase.  Thus, it is to be expected 
that if you treat patients with NAFLD with any drug that some will show an increase in 
transaminase just by chance and unrelated to the study medication. Our results show an 
increased risk of developing an increase in transaminase>3 ULN in patients with probable 
NAFLD with both agomelatine or placebo, however, the number of placebo cases are relatively 
small making an accurate assessment impossible. Therefore, we considered in other analyses 
that an elevation of transaminases to>5 or 10 ULN was more likely to be related to agomelatine 
rather than to fluctuation in NAFLD. In these analyses, a baseline increase of transaminase was 
not a risk factor for an agomelatine-associated transaminase increase. Thus, in our view, 
although the data are clear, that is if you have elevated liver enzymes at the start of treatment, 
you are more likely to show an increase in serum transaminase>3 ULN, we do not believe that 
NAFLD is an actual risk factor for agomelatine hepatoxicity.  
We observed a dose-dependent risk of transaminase increase, the pooled incidence of 
transaminase increase being 1.3 % and 2.5 % for a daily dose of 25 mg and 50 mg of 
agomelatine, respectively. Idiosyncratic hepatotoxicity is classically known to occur without 
obvious dose-dependency and in an unpredictable fashion [40]. Nevertheless, 50 mg/d of drug 
intake has been indeed suggested to be a threshold of an increased risk of transaminase [41]. 
No cases of severe liver injury, defined by the occurrence of coagulopathy or any degree of 
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encephalopathy or jaundice, of acute liver failure or of fatal outcome were observed. Of note, 
all the patients with available follow-up recovered or were recovering. The most specific 
predictor found to date of a drug’s potential for severe hepatotoxicity is the occurrence of a 
small number of cases of hepatocellular injury accompanied by increased serum total bilirubin 
(Hy’s law [42]). No cases of Hy’s law have been observed in agomelatine phase II and III 
studies. Another signal is the presence of an increase of transaminase>10 ULN. In the present 
study, 0.2 % of patients with increased transaminases classified as possibly or probably related 
to the treatment displayed such an increase. Among them, all recovered including one who 
recovered despite continuation of agomelatine.  
One striking observation of this study was that many agomelatine-treated patients 
recovered despite continuation of treatment. The phenomenon of transaminase normalisation 
despite continuation of a treatment has been called adaptation [43]. It involves genes of drug 
metabolizing enzymes and transporters. Many elevations of ALT during intake of potentially 
hepatotoxic drugs may resolve with continued therapy. This adaptation has been clearly 
demonstrated with isoniazid [review in [44]]. With these drugs, patients may exhibit a very high 
increase of ALT that can resolve completely despite maintenance of treatment. Although 
adaptation may occur with other drugs, this phenomenon is probably underestimated since the 
drug is frequently stopped when serum transaminase increases. The explanation for the 
reversible ALT elevation is not known. One possibility is that there is no relationship at all to 
liver injury capable of progressing to liver failure [45]. Another possibility is that patients who 
are unable to develop adaptation are those that tend to develop severe liver injury or even acute 
liver failure. In line with this hypothesis is that the ALT elevation observed in patients with and 
without adaptation occurred both in the majority of patients in the 12 first weeks of treatment. 
Of note, it is unlikely that a transient elevation of transaminases should have any long-term 
health consequences if adaptation occurs [45].  
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There are clear limitations to the present study. The main limitation is the well-known 
low ability of clinical trials to evaluate the association between a treatment and a liver injury as 
this adverse event is rare. Clinical trials are of short duration and may exclude patients with 
pre-existing potential risk factors for liver injury. The number of patients taking placebo was 
low. Therefore, the number of patients may be too low to clearly identify independent risk 
factors, if any, for transaminase increase. We have not studied other possible risk factors such 
as co-administration of other drugs, smoking, oral contraception or chronic viral hepatitis. The 
experts of the LSC of agomelatine have reviewed, in addition to the present cases from clinical 
trials, 390 spontaneous notifications of suspected agomelatine-induced liver injury. Many of 
these were difficult to assess as data were scarce. However, among these cases representing an 
estimated patient exposure of 13,277,836 patient-months, two cases have been associated with 
acute liver failure which were assessed as being probably related to agomelatine: in one case, 
the patient recovered after withdrawal of agomelatine and irbesartan, (the other suspected drug 
for liver failure) (unpublished case). In the other case, the outcome was favourable after a liver 
transplantation [46]. Of note, there was no follow-up of liver enzymes during agomelatine 
treatment in this case. 
The comparison of liver toxicity between antidepressant is difficult: data are scarce and 
no comparative trial focusing on this specific aim has been published.  Cases of fulminant 
hepatic failure leading to liver transplantation or death, have been reported for other 
antidepressants, including phenelzine, imipramine, amitriptyline, venlafaxine, duloxetine, 
sertraline, bupropion, trazodone) (review in {Voican, 2014 #1241}). Current data suggest that 
all antidepressants may be associated with a risk of hepatotoxicity. However, the number of 
reported cases of DILI is inevitably higher for the most frequently used antidepressants, which 
may tend to indicate, falsely, a higher hepatotoxicity rate. By contrast, is impossible to precisely 
report prevalence and severity of antidepressant-induced liver injury {Gartlehner, 2008 #1384}. 
Perlemuter G et al. Agomelatine and liver injury  18 
 
Nevertheless, it has been suggested that the incidence of antidepressant-induced liver toxicity 
requiring hospitalisation is 1.28-4 cases per 100,000 patient-years, except for nefazodone, for 
which the incidence can be estimated to be 29 cases per 100,000 patient-years {Cooper, 1988 
#1386;DeSanty, 2007 #1385} . 
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5. CONCLUSION 
In phase II and III trials, agomelatine is associated with a significant but relatively low 
risk of elevated serum transaminase>3ULN which may be increased in patients with fatty liver. 
It has been suggested that there is no advantage on depressive symptoms to increase the daily 
dose of agomelatine from 25 to 50 mg (BMJ metaanalyse). As we found a dose-dependence for 
agomelatine-induced transaminase increase, we also recommend the use of a daily dose of 25 
mg rather than 50 mg daily. No severe hepatic events were detected. In clinical practice, the 
regular monitoring of liver function tests is mandatory to identify patients with agomelatine-
related hepatotoxicity. A baseline test of transaminases, prior to the first intake of agomelatine, 
will identify patient with an underlying liver disease. Such a test will also allow identifying 
retrospectively patients with an agomelatine-related liver enzyme increase. Overall the liver 
profile of agomelatine seems safe when serum transaminases are monitored.  
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7. TABLES 
 
Table 1. Baseline characteristics of patients 
 
 
 
 
      Agomelatine 25-50 mg Placebo P-value* 
Number of patients    7,605 1,629  
   Age   Mean (±SD) 45.4 (±13.8) 48.2 (±16.5) <0.001 
   Gender  Female n (%) 5230 (68.77) 1113 (68.32) 0.724 
   BMI (kg/m²)   Mean (±SD) 26.66 (±6.29) 26.09 (±5.64) <0.001 
  <18.5 n (%) 269 (3.54) 56 (3.44)  
  [18.5-25[ n (%) 3234 (42.52) 721 (44.26)  
  [25-30[ n (%) 2355 (30.97) 527 (32.35)  
  ≥30 n (%) 1716 (22.56) 318 (19.52)  
 Weight (kg)   Mean (±SD) 74.42 (±19.61) 72.83 (±17.43)     0.001 
 Systolic blood pressure 
(mmHg) 
  Mean (±SD) 123.7 (±14.6)     125. 9 (±15.4)    <0.001 
  ≥130mmHg n (%) 2693 (35.41%)     709 (43.52%)  
  <130mmHg n (%) 4864 (63.96) 914 (56.11)  
  Diastolic blood 
pressure (mmHg) 
  Mean (±SD) 76.9 (±9.3) 77.2 (±9.9) 0.208 
  ≥ 85mmHg n (%) 1495 (19.66) 365 (22.41)  
  < 85mmHg n (%) 6062 (79.71) 1258 (77.23)  
 AST > REF n (%) 260(3.42%)       73(4.48%) 0.037 
 ALT > REF n (%) 590(7.76%)       136(8.35%) 0.422 
 ALP > REF n (%) 217(2.85%)       45(2.76%) 0.841 
 GGT > REF n (%) 735(9.66%)       185(11.36%) 0.039 
 Triglycerides > REF n (%) 1969(25.89%)     404(24.80%) 0.361 
 Glucose > REF n (%) 631(8.30%)       241(14.79%) <0.001 
(*) P-value from Student’s t-test for continuous variables and Pearson’s Chi-square test for categorical variables
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Table 2. Incidence and importance of transaminase increase according to the 
classification of the Liver Safety Committee 
 
 
 
 
Classification of cases  
by the Liver Safety Committee  
 
  
All cases N (%) 
 
Possibly or 
Probably related N (%) 
Adaptative cases 
N (%) 
25mg (N=4,957) >3 ULN 65 (1.3) 41 (0.8) 15 (0.3) 
 >10 ULN 9 (0.2) 5 (0.1) 2 (0.0) 
50mg (N=2,648) >3 ULN 66 (2.5) 45 (1.7) 16 (0.6) 
 >10 ULN 11 (0.4) 8 (0.3) 0 (0.0) 
25-50mg (N=7,605) >3 ULN 131 (1.7) 86 (1.1) 31 (0.4) 
 >10 ULN 20 (0.3) 13 (0.2) 2 (0.0) 
Placebo (N=1,629) >3 ULN 8 (0.5) - - 
 >10 ULN 1 (0.1) - - 
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Table 3. Comparison of patients with/without liver adaptation 
 
 Adaptative cases 
(n=31) 
Non-adaptative cases 
(n=108) 
p 
Age (years±SD) 47.6 (±11.3) 48.9 (±13.3) 0.62 
Gender (female, n) 19 (61.3 %) 73 (67.6 %) 0.51 
BMI (kg/m2) 28.8 (±5.5) 28.1 (±7.3) 0.63 
Systolic blood pressure (mmHg) 124.2 (±12.8) 126.6 (±14.6) 0.39 
Diastolic blood pressure (mmHg) 80.2 (±7.1) 78.9 (±8.6) 0.46 
AST  >REF, n 1 (3.2%) 13 (12.0) 0.15 
ATL >REF, n 2 (6.45%) 22 (20.4%) 0.07 
ALP >REF, n 1 (3.2%) 5 (4.63%) 0.74 
GGT >REF, n 3 (9.7%) 34 (31.5%) 0.02 
Triglycerides >REF, n 12 (38.8%) 36 (33.3 %) 0.58 
Glucose >REF, n 5 (16.1%) 11 (10.2%) 0.36 
 
REF, reference value, AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, 
gamma-glutamyltransferase; ALP, alkaline phosphatases; REF, reference value. 
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Table 4. Risk factors of transaminase increase 
   Agomelatine 25-50mg  Placebo 
Model 
 Effective 
 by classes 
Event  
by 
classes 
HR [95CI%] Effective 
 by classes 
Event  
by classes 
HR [95CI%] 
Age (years) >65 vs ≤65 557 vs 7048 10 vs 121 1.04[0.54;1.98] 263 vs 1366 2 vs 6 1.72[0.35;8.59] 
Gender Female vs Male 5230 vs 2375 85 vs 46 0.83[0.58;1.18] 1113 vs 516 7 vs 1 3.34[0.41;27.25] 
Baseline AST  >REF vs ≤REF 260 vs 7345 13 vs 118 3.41[1.92;6.04]** 73 vs 1556 1 vs 7 3.59[0.44;29.27] 
Baseline ALT >REF vs ≤REF 590 vs 7015 20 vs 111 2.29[1.42;3.69]** 136 vs 1493 4 vs  4 10.69[2.67;42.75]** 
Baseline ALT or AST >REF vs ≤REF 675 vs 6930 23 vs 108 2.35[1.50;3.69]** 157 vs 1472 4 vs 4 9.35[2.34;37.42]* 
Baseline GGT >REF vs ≤REF 735 vs 6870 33 vs 98 3.23[2.18;4.79]** 185 vs 1444 4 vs 4 8.14[2.04;32.56]* 
Baseline Triglycerides >REF vs ≤REF 1969 vs 5589 45 vs 84 1.49[1.03;2.13]* 404 vs 1206 3 vs 5 1.79[0.43;7.52] 
Baseline ALP >REF vs ≤REF 217 vs 7388 5 vs 126 1.35[0.55;3.29] 45 vs 1584 1 vs 7 5.74[0.70;47.04] 
Metabolic syndrome  Yes vs No 1112 vs 6493 36 vs 95 2.08[1.42;3.06]** 242  vs 1387 1 vs 7 0.78[0.10;6.31] 
 - BMI (kg/m²) ≥30 vs <30 1716 vs  5858 45 vs  86 1.67[1.17;2.40]* 318 vs 1304  1 vs  7 0.56[0.07;4.55] 
 -Elevated Triglyceride Yes vs No 2501 vs 5104 53 vs 78 1.35[0.95;1.92] 517 vs 1112 3 vs 5 1.30[0.31;5.45] 
 -Elevated Cholesterol Yes vs No 759 vs 6846 24 vs 107 1.89[1.21;2.94]* 163 vs 1466 8 vs 0 NA 
 -Elevated blood 
pressure 
Yes vs No 
3370 vs 4235 70 vs 61 1.39[0.98;1.96] 830 vs 799 4 vs 4 0.90 [0.22;3.59] 
 - Elevated blood 
glucose 
Yes vs No 
842 vs 6763 17 vs 114 1.18[0.71;1.97] 197 vs 1432 1 vs 7 0.95 [0.12;7.74] 
 
** <0.001 ; * <0.05 
Metabolic syndrome is defined by the presence of at least 3 of the following factors: BMI ≥ 30 kg/m², elevated 
triglycerides (medical history or ≥ 1.6mmol/L), elevated cholesterol (medical history or ≥ 8 mmol/L), elevated 
blood pressure (medical history, SBP≥130 mmHg or DBP ≥ 85 mmHg), elevated blood glucose (medical history 
or ≥6.1 mmol/L). AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-
glutamyltransferase; ALP, alkaline phosphatases; REF, reference value. 
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Table 5. Transaminase elevation according to baseline level of transaminase 
 
 
 Agomelatine Placebo Cox proportional hazard models Interaction   
  P-value 
  
 
N n(%) N n(%) Hazard Ratio [95%CI] P-value 
AST or ALT > 3 ULN 
  Baseline ≤ REF 6930 108(1.56) 1472 4(0.27) 4.10 [1.51;11.13] 0.006  
  Baseline > REF 674   23(3.41) 157 4(2.55) 0.98 [0.34; 2.85] 0.973 0.0556 
AST or ALT > 5 ULN 
  Baseline ≤ REF 6930 54(0.78) 1472 3(0.20) 2.61 [0.81; 8.36] 0.107  
  Baseline > REF 674   9(1.34) 157 2(1.27) 0.73 [0.16; 3.39] 0.686 0.2032 
AST or ALT > 10 ULN 
  Baseline ≤ REF 6930 19(0.27) 1472 1(0.07)    
  Baseline > REF 674   1(0.15) 157 0(0.00)    
Hazard Ratio were not provided for AST or ALT >10 ULN due to the small number of cases. 
REF, reference value. 
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8. FIGURE LEGENDS 
 
Figure 1 
Flow chart. Inclusion of patients and analyses by the Liver Safety Committee. 
 
Figure 2 
Time to onset of transaminase increase in cases classified as probably or possibly related 
to agomelatine. A. In all patients possibly/probably related (N=86). B. In patients with adaptive 
phenomenon (N=31). 
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